barchart.com
Crohns' Disease Pipeline Appears Robust With 90+ Key Pharma Companies Actively ...
There are many new drugs and trials underway for Crohn’s disease, which could expand future treatment options. Recent phase 2 and phase 3 starts from major pharma show active investment in IBD research.
Knowing which drugs and companies are active helps patients and clinicians track emerging therapies and potential trial opportunities.
Adult patients with Crohn’s disease, clinicians treating IBD, researchers following drug development, and patients interested in clinical trials or future treatment options.
What To Know
DelveInsight’s Crohn’s Disease Pipeline Insight 2026 report, summarized in this press-release-style article, reviews more than 90 companies and 90+ pipeline therapies in development for Crohn’s disease.
The piece lists recent clinical trial starts and sponsors (for example, phase 3 and phase 2 studies from Janssen, AbbVie, Eli Lilly, AstraZeneca) and names many drugs and companies working in the space. This article is a market/report summary rather than original clinical data.
It highlights active development across many drug classes (biologics, small molecules, S1P modulators, etc.) and names individual drugs and study actions such as phase 3 initiations and combination studies. It does not provide patient-level results or new efficacy/safety findings.
If you follow IBD treatment development, this is useful to see which companies and drug candidates are active and which trials have recently started or been announced. It can help you spot drugs you may hear about in future trial recruitment or approval news.
For details on specific drugs, trial designs, eligibility, or results, consult the primary trial registries, company press releases, or your clinical team.
This article is a press-release-style market summary based on DelveInsight’s paid report and company announcements; it lists drugs and trial starts but does not report trial results or regulatory decisions. For clinical implications, rely on peer-reviewed studies, trial registries, and regulatory agency communications.
